4/11
05:32 am
mist
Milestone Pharmaceuticals (MIST) was upgraded by Raymond James Financial, Inc. to "strong-buy".
Low
Report
Milestone Pharmaceuticals (MIST) was upgraded by Raymond James Financial, Inc. to "strong-buy".
4/10
09:00 am
mist
Milestone Pharmaceuticals (MIST) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $6.00 price target on the stock.
Low
Report
Milestone Pharmaceuticals (MIST) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $6.00 price target on the stock.
4/10
08:00 am
mist
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Medium
Report
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
4/7
08:30 am
mist
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Low
Report
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
4/2
08:00 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/31
08:00 am
mist
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
High
Report
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
3/22
10:24 pm
mist
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
Medium
Report
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
3/20
09:52 am
mist
Milestone Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
3/20
08:24 am
mist
Milestone Pharmaceuticals GAAP EPS of -$0.75, revenue of $1.55M [Seeking Alpha]
Medium
Report
Milestone Pharmaceuticals GAAP EPS of -$0.75, revenue of $1.55M [Seeking Alpha]
3/20
07:56 am
mist
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT [Yahoo! Finance]
3/16
08:23 am
mist
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
3/16
08:13 am
mist
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
Low
Report
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
3/14
02:56 am
mist
Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality [Seeking Alpha]
Low
Report
Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality [Seeking Alpha]
3/12
08:12 am
mist
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 [Yahoo! Finance]
Neutral
Report
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 [Yahoo! Finance]
3/12
08:00 am
mist
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Low
Report
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
2/26
08:34 am
mist
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/26
08:00 am
mist
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Low
Report
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
2/26
06:28 am
mist
Milestone Pharmaceuticals (MIST) was downgraded by Zacks Research from "strong-buy" to "hold".
Neutral
Report
Milestone Pharmaceuticals (MIST) was downgraded by Zacks Research from "strong-buy" to "hold".
2/10
08:00 am
mist
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Low
Report
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
2/3
08:00 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/28
07:29 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/27
08:33 am
mist
Milestone Pharmaceuticals announces U.S. availability of cardamyst [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals announces U.S. availability of cardamyst [Yahoo! Finance]
1/26
08:18 am
mist
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
1/26
08:00 am
mist
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Low
Report
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)